Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19

niversitätsklinikum Tübingen0 个研究点目标入组 220 人开始时间: 2020年3月24日最近更新: 2021年3月17日

适应症

试验速览

暂无简介。

•Written informed consent
•Age above 18 years
•Women of childbearing age only: Must agree to practice continuous effective contraception for the duration of the study (a method which results in a failure rate less than 1% per year)
•Disease severe enough to require hospitalisation
•QTc interval lower than 450 msec
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 195
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 25

•Respiratory rate >24/min
•Pregnancy or lactation
•Weight <50 kg
•Hemodynamic/rhythm instability
•Acute myocardial infarction Type 1
•Use of concomitant medications that prolong the QT/QTc interval.
•Any regular concomitant medication which is contraindicated in the use together with HCQ
•Hypersensitivity to Hydroxychloroquine, Chloroquine or other 4-Aminoquinolines
•Pre-existing retinopathy or maculopathy
•Known Glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, Favism)
•Haematopoietic systems diseases
•Myasthenia gravis
•Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

发起方

niversitätsklinikum Tübingen